Your browser doesn't support javascript.
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Huang, Dong; Yu, He; Wang, Ting; Yang, Huan; Yao, Rong; Liang, Zongan.
  • Huang D; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yu H; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Wang T; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yang H; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yao R; Emergency Medical Laboratory, Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Liang Z; Disaster Medical Center, Sichuan University, Chengdu, Sichuan, China.
J Med Virol ; 93(1): 481-490, 2021 01.
Article in English | MEDLINE | ID: covidwho-1206788
ABSTRACT
We conducted this systemic review and meta-analysis in an attempt to evaluate the efficacy and safety of umifenovir in coronavirus disease 2019 (COVID-19). We searched PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, and medRxiv database. We included both retrospective and prospective studies. The mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) were applied to assess the effectiveness of umifenovir for COVID-19. A total of 12 studies with 1052 patients were included in our final studies. Compared with control group, umifenovir was associated with higher negative rate of PCR on day 14 (RR1.27; 95% CI 1.04 to 1.55). However, umifenovir is not related to nucleus acid negative conversion time (MD 0.09; 95% CI -1.48 to 1.65), negative rate on day 7 (RR1.09; 95% CI 0.91 to 1.31), incidence of composite endpoint (RR1.20; 95% CI 0.61 to 2.37), rate of fever alleviation on day 7 (RR1.00; 95% CI 0.91 to 1.10), rate of cough alleviation on day 7 (RR1.00; 95% CI 0.85 to 1.18), or hospital length of stay (MD 1.34; 95% CI -2.08 to 4.76). Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events 1.29; 95% CI 0.57 to 2.92). The results of sensitivity analysis and subgroup analysis were similar to pooled results. There is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Indoles Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26256

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / SARS-CoV-2 / COVID-19 Drug Treatment / Indoles Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: J Med Virol Year: 2021 Document Type: Article Affiliation country: Jmv.26256